In vitro, NK cells respond to and kill an EBV-positive B cell line more efficiently when these cells are in the lytic as compared to the latent phase of infection (51–53), in particular NK cells with the NKG2A+KIR− phenotype (46). The gene discussed is KLRC1; the disease is infection.